Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Calgary

$100,000.00

How Does ING5 Promote Cell Stemness?

FY 2016-17

Summary
Despite treatment using surgery followed by radiation and chemotherapy, only 5% of patients with the most common form of brain cancer called glioblastoma multiforme survive 5 years after diagnosis. It is thought that these cancers reappear due to the existence of a small population of unspecialized cells called brain tumour initiating cells (BTICs) that are resistant to treatment, grow slowly and retain the ability to divide. After treatment these BTICs later give rise to more specialized and rapidly growing cells that develop into secondary malignancies, and it is these cancers that are most frequently the cause of death in patients. Therefore, defining properties in this population of BTICs that may make them more sensitive to treatment could have very beneficial consequences if these weaknesses can be exploited. We have recently found that a protein we named INhibitor of Growth 5 (ING5) has the ability to make cells remain in a BTIC-like state and prevent them from becoming more specialized. By blocking the production or activity of ING5, cells become more specialized, and we believe that this will make BTICs more sensitive to radiation and chemotherapeutics. If this idea is supported by our study, it should improve the efficiency of treatment, and consequently increase patient survival. We propose to test this idea using a unique panel of BTIC cells we have that represent several different subtypes of brain cancer. We will use methods to both block production of ING5 and to inhibit its activity, and then test whether BTICs are more sensitive to commonly used brain cancer chemotherapeutics such as the current standard of care, the chemical temozolomide. If this strategy is successful, it should be useful in other cancer types that are also thought to recur due to similar populations of tumour initiating cells that are particularly resistant to treatment due to their unspecialized and slow growing nature.
Program
Project Grant
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
366577
Name
Riabowol Karl T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
How Does ING5 Promote Cell Stemness?
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Brain Tumor Initiating Cell; Cancer; Chromatin; Epigenetic; Glioblastoma; Ing Proteins; Tumour Suppressor
Abstract
Despite treatment using surgery followed by radiation and chemotherapy, only 5% of patients with the most common form of brain cancer called glioblastoma multiforme survive 5 years after diagnosis. It is thought that these cancers reappear due to the existence of a small population of unspecialized cells called brain tumour initiating cells (BTICs) that are resistant to treatment, grow slowly and retain the ability to divide. After treatment these BTICs later give rise to more specialized and rapidly growing cells that develop into secondary malignancies, and it is these cancers that are most frequently the cause of death in patients. Therefore, defining properties in this population of BTICs that may make them more sensitive to treatment could have very beneficial consequences if these weaknesses can be exploited. We have recently found that a protein we named INhibitor of Growth 5 (ING5) has the ability to make cells remain in a BTIC-like state and prevent them from becoming more specialized. By blocking the production or activity of ING5, cells become more specialized, and we believe that this will make BTICs more sensitive to radiation and chemotherapeutics. If this idea is supported by our study, it should improve the efficiency of treatment, and consequently increase patient survival. We propose to test this idea using a unique panel of BTIC cells we have that represent several different subtypes of brain cancer. We will use methods to both block production of ING5 and to inhibit its activity, and then test whether BTICs are more sensitive to commonly used brain cancer chemotherapeutics such as the current standard of care, the chemical temozolomide. If this strategy is successful, it should be useful in other cancer types that are also thought to recur due to similar populations of tumour initiating cells that are particularly resistant to treatment due to their unspecialized and slow growing nature.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Riabowol, Karl T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
University of Calgary - $100,000 Grant (2016-17) | Canada Spends